Statins for the primary prevention of cardiovascular disease

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Ebrahim, Shah ^a   Taylor, Fiona C ^a   Brindle, Peter ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Bristol Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; DRUG INTERACTION; HUMAN; MALE; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84893219937     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g280     Document Type: Article

References (36)

1. QIntervention. QRISK. ClinRisk, University of Nottingham, 2012. http://qintervention.org/index.php.
2. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95-112.
3. Bonetti P, Lerman L, Napoli C, Lerman A. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003;24:225-48.
4. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-79.
5. Manuel D, Kwong K, Tanuseputro P, Lim J, Mustard C, Anderson GM, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modeling study. BMJ 2006;332:1419.
6. National Institute for Health and Care Excellence. Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease (Technology appraisal TA94). 2006. www.nice.org.uk/TA094.
7. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1345-61.
8. Prescriptions Dispensed in the Community: England, Statistics for 2001 to 2011. Health and Social Care Information Centre, 2011. https://catalogue.ic. nhs.uk/publications/prescribing/primary/pres-disp-com-eng-2001-11/ pres-disp-com-eng-2001-11-rep.pdf.
9. Cholesterol Treatment Trialists (CTT) Collaboration. The effects of lowering LDL cholesterolwith statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;378:67-5.
10. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
11. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
12. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123.
13. Huffman M, Taylor F, Ebrahim S. Should people at low risk of cardiovascular disease take a statin? www.bmj.com/content/347/bmj.f6123/rr/ 674751.
14. Abramson JD, Rosenberg H, Jewell N, Wright JM. Authors response to the Cochrane review authors. www.bmj.com/content/347/bmj.f6123/rr/678736.
15. Ray KK, Seshasai S, Erqou S, Sever P, Jukema W, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention. Arch Intern Med 2010;170:1024-31.
16. Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDLcholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27randomised trials of statin therapy. PLoS One 2012;7:e29849.
17. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90.
18. Golomb B, Evans M, Dimsdale J, White H. Effects of statin on energy and fatigue and exertion: results from a randomised controlled trial. Arch Intern Med 2012;172:1180-2.
19. Wardle J, Armitage J, Collins R, Wallendszus K, Keech A, Lawson A. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. BMJ 1996;313:75-8.
20. Perez AC, Jhund P, Preiss D, Kjekshus J, McMurray JJ. Effect of rosuvastatin on fatigue in patients with heart failure. J Am Coll Cardiol 2013;61:1121-2.
21. Golomb B, Evans M. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418.
22. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
23. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109.
24. Beers MH, Berkow R, eds. The Merck manual of diagnosis and therapy . 2013. www.merck.com.
25. Cheung BMY, Lam KSL. Is intensive LDL-cholesterol lowering beneficial and safe? Lancet 2010;376:1622-4.
26. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170, 255 patients from randomized trials. QJM 2011;104:109-24.
27. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64.
28. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45.
29. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage. a meta-analysis of 31 randomized controlled trials. Stroke 2012;43:2149-56.
30. Smeeth L, Hemingway H. Improving vascular health: are pills the answer? BMJ 2012;344:e3802.
31. National Institute for Health and Care Evidence. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (Clinical guideline 67.) 2010. http://guidance.nice.org.uk/cg67.
32. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2013. doi:10.1016/j.jacc.2013.11.002.
33. Food and Drugs Administration. FDA expands advice on statin risks. 2012. www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm.
34. Medicines and Healthcare products Regulatory Agency. Statins: risk of hyperglycaemia and diabetes. Drug Safety Update 2012;5:A2. www.mhra.gov.uk/ Safetyinformation/DrugSafetyUpdate/CON140667.
35. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7.
36. Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011;365:285-7.